These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37919738)

  • 1. The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.
    Wang C; Lu N; Yan L; Li Y
    Virol J; 2023 Nov; 20(1):252. PubMed ID: 37919738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.
    Cassidy T; Craig M
    PLoS Comput Biol; 2019 Nov; 15(11):e1007495. PubMed ID: 31774808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
    Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.
    Ahamadi M; Kast J; Chen PW; Huang X; Dutta S; Upreti VV
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):250-260. PubMed ID: 36564918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
    Johnson DB; Puzanov I; Kelley MC
    Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH
    J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
    Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.